On March 9, 2020, Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it has agreed to pay a $65 million penalty to settle charges brought by the U.S. Attorney's Office for the Southern District of New York.  The settlement is subject to court approval.  The SEC's complaint alleges that Acorda violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations, Acorda has agreed to pay a penalty of $65 million, which is a 13.1% decrease over the first quarter of the year.  The settlement is subject to court approval, and the amount of the penalty will be determined by the court at a later date.  The SEC's continuing investigation is being conducted by Boobalan Pachaiyappan, Michael Gesser, and Jan Folena of the Boston Regional Office.  The SEC appreciates the assistance of the U.S. Attorney's Office for New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.